Long-term, open-label study of once-daily ropinirole prolonged release in early parkinson's disease

International Journal of Neuroscience

Volumn 121, Issue 5, 2011, Pages 246-253

  Hauser, Robert A ^a   Reichmann, Heinz ^b   Lew, Mark ^c   Asgharian, Afsaneh ^d   Makumi, Clare ^d   Shulman, Kenneth J ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Efficacy; long term; Parkinson's disease; ropinirole prolonged release; safety; treatment

Indexed keywords

AMANTADINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE; ENTACAPONE; LEVODOPA; RASAGILINE; ROPINIROLE; SELEGILINE; UBIDECARENONE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED DRUG RELEASE; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FALLING; FATIGUE; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; INSOMNIA; LEG PAIN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; OPTIMAL DRUG DOSE; PARANOIA; PARKINSON DISEASE; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME;

EID: 79955825965     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2010.546538     Document Type: Article

References (7)

1. Grosset, K. A., Reid, J. L., & Grosset, D. G. (2005). Medicine-taking behavior: Implications of suboptimal compliance in Parkinson's disease. Movement Disorders, 20, 1397-404. (Pubitemid 43072646)
2. Holloway, R. G., Shoulson, I., Fahn, S., Kieburtz, K., Lang, A., Marek, K. et al. (2004). Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Archives of Neurology, 61, 1044-1053. (Pubitemid 38915945)
3. Pahwa, R., Stacy, M. A., Factor, S. A. et al. (2007). Ropini-role 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology, 68, 1108-1115. (Pubitemid 46559844)
4. Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000). A fve-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. New England Journal of Medicine, 342, 1484-1491. (Pubitemid 30318272)
5. Stocchi, F., Hersh, B. P., Scott, B. L., Nausieda, P. A., Giorgi L, & the Ease-PD Monotherapy Study Investigators. (2008). Ropini-role 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: A randomized, double-blind, non-inferiority crossover study. Current Medical Research and Opinion, 24(10), 2883-2895.
6. Tompson, D., & Vearer, D. (2007). Steady-state pharmacoki-netic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson's disease. Clinical Therapeutics, 29, 2654-2666.
7. Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nah-mias, C. et al. (2003). Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology, 54, 93-101. (Pubitemid 36764985)